Telix Pharmaceuticals Ltd
TLXDrugs in Pipeline
6
Phase 3 Programs
5
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
Standard of Care
Metastatic Prostate Cancer
177Lu-TLX591
Metastatic Castration-resistant Prostate Cancer
68Ga-PSMA-11
Biochemical Recurrence of Malignant Neoplasm of Prostate
89Zr-TLX250 PET/CT
Clear Cell Renal Cell Carcinoma
Enzalutamide
Metastatic Castration-resistant Prostate Cancer
177Lu-DOTA-TLX591
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Standard of Care | Phase 3 | Metastatic Prostate Cancer | - | - |
177Lu-TLX591 | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
68Ga-PSMA-11 | Phase 3 | Biochemical Recurrence of Malignant Neoplasm of Prostate | - | - |
89Zr-TLX250 PET/CT | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
Enzalutamide | Phase 3 | Metastatic Castration-resistant Prostate Cancer | - | - |
177Lu-DOTA-TLX591 | Phase 2 | Prostate Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Telix Pharmaceuticals Ltd's drug pipeline?→
CatalystAlert tracks 6 drug candidates in Telix Pharmaceuticals Ltd's (TLX) pipeline across Phase 3, Phase 2. Its lead program is Standard of Care (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Telix Pharmaceuticals Ltd's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Telix Pharmaceuticals Ltd (TLX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track TLX biotech catalysts?→
Add TLX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Telix Pharmaceuticals Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.